-+ 0.00%
-+ 0.00%
-+ 0.00%

Adagio Medical FULCRUM-VT trial meets endpoints for vCLAS ventricular ablation system

PUBT·04/26/2026 13:32:19
Listen to the news
Adagio Medical FULCRUM-VT trial meets endpoints for vCLAS ventricular ablation system
  • Adagio Medical reported positive six-month results from FULCRUM-VT, pivotal IDE trial supporting planned FDA premarket approval filing for vCLAS ventricular ablation system.
  • Data were presented in late-breaking clinical trial session at Heart Rhythm Society 2026 conference.
  • Trial met safety, effectiveness endpoints, showing meaningful reductions in ICD shocks, VT recurrence, antiarrhythmic drug use.
  • Results were consistent across ischemic, non-ischemic cardiomyopathy patients, supporting endocardial-only approach as potential broader-use VT option.
  • Study enrolled 209 patients across 20 centers in US, Canada, positioning program for regulatory step-up in ventricular ablation market.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adagio Medical Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604260932BIZWIRE_USPR_____20260426_BW316811) on April 26, 2026, and is solely responsible for the information contained therein.